Emily S Ford1,2, Amalia S Magaret3,4,2, Cedric W Spak5,6, Stacy Selke3, Steve Kuntz3, Lawrence Corey1,3,2, Anna Wald1,3,7,2. 1. Department of Medicine. 2. Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle Washington. 3. Department of Laboratory Medicine. 4. Department of Biostatistics. 5. Simmons Transplant Institute, Dallas. 6. Baylor All Saints Medical Center, Fort Worth, Texas, USA. 7. Department of Epidemiology, University of Washington.
Abstract
OBJECTIVES: HIV-infected persons with chronic herpesvirus infections may experience paradoxical worsening after initiation of antiretroviral therapy (ART), but the impact of longer term ART is unclear. We evaluated the relationships between genital herpes simplex virus (HSV) shedding and ART initiation and time on therapy in HIV and HSV-2-infected persons. DESIGN: Prospective observational study. METHODS: Rates of HSV shedding in 45 HIV and HSV-2-infected persons on or off ART were prospectively followed over up to three, noncontiguous, 60-day periods, during which participants performed daily genital swabs for HSV detection by real-time HSV DNA PCR and reported symptoms. Initiation or discontinuation of ART was at the discretion of participants' healthcare providers. RESULTS: In all, 6425 daily genital swabs were obtained from 45 persons (38 men and seven women) during 105 swabbing sessions. During the three sessions, 67, 74, and 92% of persons were on ART. HSV was detected on 26.5% of days in men and 22.3% of days in women. The overall rates of genital HSV shedding were 19.4% of days in persons not on ART, 30.2% in persons within 90 days of ART initiation, and 23.3% in persons on ART for longer than 90 days. After initiation of ART, HSV shedding decreased by 2% per month, or 23% per year (RR 0.98/month on ART; P = 0.0003 in adjusted analysis). This finding was consistent after including consideration of HIV viral load and CD4 cell count. CONCLUSIONS: HSV shedding increased significantly shortly after ART initiation, but decreased with time on prolonged ART.
OBJECTIVES:HIV-infected persons with chronic herpesvirus infections may experience paradoxical worsening after initiation of antiretroviral therapy (ART), but the impact of longer term ART is unclear. We evaluated the relationships between genital herpes simplex virus (HSV) shedding and ART initiation and time on therapy in HIV and HSV-2-infectedpersons. DESIGN: Prospective observational study. METHODS: Rates of HSV shedding in 45 HIV and HSV-2-infectedpersons on or off ART were prospectively followed over up to three, noncontiguous, 60-day periods, during which participants performed daily genital swabs for HSV detection by real-time HSV DNA PCR and reported symptoms. Initiation or discontinuation of ART was at the discretion of participants' healthcare providers. RESULTS: In all, 6425 daily genital swabs were obtained from 45 persons (38 men and seven women) during 105 swabbing sessions. During the three sessions, 67, 74, and 92% of persons were on ART. HSV was detected on 26.5% of days in men and 22.3% of days in women. The overall rates of genital HSV shedding were 19.4% of days in persons not on ART, 30.2% in persons within 90 days of ART initiation, and 23.3% in persons on ART for longer than 90 days. After initiation of ART, HSV shedding decreased by 2% per month, or 23% per year (RR 0.98/month on ART; P = 0.0003 in adjusted analysis). This finding was consistent after including consideration of HIV viral load and CD4 cell count. CONCLUSIONS: HSV shedding increased significantly shortly after ART initiation, but decreased with time on prolonged ART.
Authors: Sara Gianella; Andrew D Redd; Mary K Grabowski; Aaron A R Tobian; David Serwadda; Kevin Newell; Eshan U Patel; Sarah Kalibbala; Paschal Ssebbowa; Ronald H Gray; Thomas C Quinn; Steven J Reynolds Journal: J Infect Dis Date: 2015-03-05 Impact factor: 5.226
Authors: Dirk P Dittmer; Kristen Tamburro; Huichao Chen; Anthony Lee; Marcia K Sanders; Tischan A Wade; Sonia Napravnik; Jennifer Webster-Cyriaque; Mahmoud Ghannoum; Caroline H Shiboski; Judith A Aberg Journal: AIDS Date: 2017-09-24 Impact factor: 4.177
Authors: Rachel D Schrier; Mi-Kyoung Song; Irene L Smith; Marietta P Karavellas; Dirk-Uwe Bartsch; Francesca J Torriani; Claudio R Garcia; William R Freeman Journal: Retina Date: 2006-02 Impact factor: 4.256
Authors: Kenneth H Fife; Kenneth Mugwanya; Katherine K Thomas; Jared M Baeten; Connie Celum; Elizabeth Bukusi; Guy de Bruyn; Andrew Mujugira; Bellington Vwalika; Anna Wald; Jairam R Lingappa Journal: J Infect Dis Date: 2015-12-23 Impact factor: 5.226
Authors: Eva María Gutiérrez-Delgado; Hiram Villanueva-Lozano; Miguel J García Rojas-Acosta; Ivett C Miranda-Maldonado; Javier Ramos-Jiménez Journal: Ann Med Surg (Lond) Date: 2016-11-09
Authors: Tajanna Stinn; Steve Kuntz; Dana Varon; Meei-Li Huang; Stacy Selke; Samuel Njikan; Emily S Ford; Joan Dragavon; Robert W Coombs; Christine Johnston; Marta E Bull Journal: J Virol Date: 2020-12-09 Impact factor: 5.103
Authors: Rebecca G Nowak; Tobias A Liska; Søren M Bentzen; Esther Kim; Tsungai Chipato; Robert A Salata; David D Celentano; Charles S Morrison; Patti E Gravitt Journal: J Acquir Immune Defic Syndr Date: 2021-06-01 Impact factor: 3.771
Authors: Romain Silhol; Helen Coupland; Rebecca F Baggaley; Lori Miller; Lisa Staadegaard; Sami L Gottlieb; James Stannah; Katherine M E Turner; Peter Vickerman; Richard Hayes; Philippe Mayaud; Katharine J Looker; Marie-Claude Boily Journal: J Acquir Immune Defic Syndr Date: 2021-09-01 Impact factor: 3.771